Article By:
James Gornick
Tuesday, November 24, 2020 7:18 AM EST
The trends in the final months of 2020 and moving into 2021 have assembled "The Dream-Team" in saving many lives and the losses in functionalities in those infected with COVID-19 World-Wide Pandemic.
In this article: AZN, JNJ, PFE, CYDY, ABIO, REGN, SPPI, MRNA, AXDX, CAPR, MESO, NVS Also: INO, SRNE, NVAX, DVAX, CRSP
Is There A Light At The End Of The Tunnel For A COVID-19 Therapeutic?
I tried to buy $CYDY based on your recommendation, but e-trade, which is supposedly commission free, would have charged me a commission. Any idea why? They haven't charged me commissions on any other stocks I've bought through them. I emailed to enquire but never heard back.
Is There A Light At The End Of The Tunnel For A COVID-19 Therapeutic?
Great article on $CYDY as always.
CytoDyn Investors Sell Despite Positive Recommendation From DSMB And A More Certain Path To COVID-19 Approval
I'm surprised there's not more love for $CYDY.
CytoDyn Investors Sell Despite Positive Recommendation From DSMB And A More Certain Path To COVID-19 Approval
Appreciate your putting $CYDY on my radar. Been following it since you first started writing about them.
CytoDyn Investors Sell Despite Positive Recommendation From DSMB And A More Certain Path To COVID-19 Approval
Good to know on $CYDY.
CytoDyn’s Data: Approvable Drug Sets Stage For Near-Term Move Upward
Perhaps I should have listened to you and stuck to forex which I know. $CYDY is down quite a bit since I first read this.
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
It's very hard to know who/what to believe about $CYDY. There seems to be so much conflicting info.
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Good article, but my enthusiasm for $CYDY has really waned after reading some of Ketan Desai's comments.
CytoDyn’s Data: Approvable Drug Sets Stage For Near-Term Move Upward
When will your next article on $CYDY be out?
CytoDyn’s Data: Approvable Drug Sets Stage For Near-Term Move Upward
Ketan Desai, I think it's rare for authors to cover a stock with a completely unbiased view. Most write about a company because they feel strongly one way or the other.
Personally, I feel it's the reader's obligation to do some due diligence and seek out differing opinions and then make an informed decision on whether to invest. That's one of the reasons I love this site - I can read what different intelligent contributors have to say about the same stock. Unfortunately, there isn't much coverage on $CYDY. I think it would be great if you wrote an article about this stock as well so we could see some differing opinions. If you add up all your comments, the article is practically already written!